Sökning: WFRF:(LARSSON L) > (2000-2009) > Effects of chemothe...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 19917naa a2205521 4500 | |
001 | oai:lup.lub.lu.se:f44fbf14-97ee-4bb3-ab34-14b5246b5cfe | |
003 | SwePub | |
008 | 160405s2005 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/2432172 URI |
024 | 7 | a https://doi.org/10.1016/S0140-6736(05)66544-02 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Abe, O4 aut |
245 | 1 0 | a Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials |
264 | 1 | c 2005 |
520 | a Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Abe, R4 aut |
700 | 1 | a Enomoto, K4 aut |
700 | 1 | a Kikuchi, K4 aut |
700 | 1 | a Koyama, H4 aut |
700 | 1 | a Masuda, H4 aut |
700 | 1 | a Nomura, Y4 aut |
700 | 1 | a Sakai, K4 aut |
700 | 1 | a Sugimachi, K4 aut |
700 | 1 | a Tominaga, T4 aut |
700 | 1 | a Uchino, J4 aut |
700 | 1 | a Yoshida, M4 aut |
700 | 1 | a Haybittle, JL4 aut |
700 | 1 | a Davies, C4 aut |
700 | 1 | a Harvey, VJ4 aut |
700 | 1 | a Holdaway, TM4 aut |
700 | 1 | a Kay, RG4 aut |
700 | 1 | a Mason, BH4 aut |
700 | 1 | a Forbes, JF4 aut |
700 | 1 | a Wilcken, N4 aut |
700 | 1 | a Gnant, M4 aut |
700 | 1 | a Jakesz, R4 aut |
700 | 1 | a Ploner, M4 aut |
700 | 1 | a Yosef, HMA4 aut |
700 | 1 | a Focan, C4 aut |
700 | 1 | a Lobelle, JP4 aut |
700 | 1 | a Peek, U4 aut |
700 | 1 | a Oates, GD4 aut |
700 | 1 | a Powell, J4 aut |
700 | 1 | a Durand, M4 aut |
700 | 1 | a Mauriac, L4 aut |
700 | 1 | a Di Leo, A4 aut |
700 | 1 | a Dolci, S4 aut |
700 | 1 | a Piccart, MJ4 aut |
700 | 1 | a Masood, MB4 aut |
700 | 1 | a Parker, D4 aut |
700 | 1 | a Price, JJ4 aut |
700 | 1 | a Hupperets, PSGJ4 aut |
700 | 1 | a Jackson, S4 aut |
700 | 1 | a Ragaz, J4 aut |
700 | 1 | a Berry, D4 aut |
700 | 1 | a Broadwater, G4 aut |
700 | 1 | a Cirrincione, C4 aut |
700 | 1 | a Muss, H4 aut |
700 | 1 | a Norton, L4 aut |
700 | 1 | a Weiss, RB4 aut |
700 | 1 | a Abu-Zahra, HT4 aut |
700 | 1 | a Portnoj, SM4 aut |
700 | 1 | a Baum, M4 aut |
700 | 1 | a Cuzick, J4 aut |
700 | 1 | a Houghton, J4 aut |
700 | 1 | a Riley, D4 aut |
700 | 1 | a Gordon, NH4 aut |
700 | 1 | a Davis, HL4 aut |
700 | 1 | a Beatrice, A4 aut |
700 | 1 | a Mihura, J4 aut |
700 | 1 | a Naja, A4 aut |
700 | 1 | a Lehingue, Y4 aut |
700 | 1 | a Romestaing, P4 aut |
700 | 1 | a Dubois, JB4 aut |
700 | 1 | a Delozier, T4 aut |
700 | 1 | a Mace-Lesec'h, J4 aut |
700 | 1 | a Rambert, P4 aut |
700 | 1 | a Andrysek, O4 aut |
700 | 1 | a Barkmanova, J4 aut |
700 | 1 | a Owen, JR4 aut |
700 | 1 | a Meier, P4 aut |
700 | 1 | a Howell, A4 aut |
700 | 1 | a Ribeiro, GC4 aut |
700 | 1 | a Swindell, R4 aut |
700 | 1 | a Alison, R4 aut |
700 | 1 | a Boreham, J4 aut |
700 | 1 | a Clarke, M4 aut |
700 | 1 | a Collins, R4 aut |
700 | 1 | a Darby, S4 aut |
700 | 1 | a Davies, C4 aut |
700 | 1 | a Elphinstone, P4 aut |
700 | 1 | a Evans, V4 aut |
700 | 1 | a Godwin, J4 aut |
700 | 1 | a Gray, R4 aut |
700 | 1 | a Harwood, C4 aut |
700 | 1 | a Hicks, C4 aut |
700 | 1 | a James, S4 aut |
700 | 1 | a MacKinnon, E4 aut |
700 | 1 | a McGale, P4 aut |
700 | 1 | a McHugh, T4 aut |
700 | 1 | a Mead, G4 aut |
700 | 1 | a Peto, R4 aut |
700 | 1 | a Wang, Y4 aut |
700 | 1 | a Albano, J4 aut |
700 | 1 | a de Oliveira, CF4 aut |
700 | 1 | a Gervasio, H4 aut |
700 | 1 | a Gordilho, J4 aut |
700 | 1 | a Johansen, H4 aut |
700 | 1 | a Mouridsen, HT4 aut |
700 | 1 | a Gelman, RS4 aut |
700 | 1 | a Harris, JR4 aut |
700 | 1 | a Henderson, IC4 aut |
700 | 1 | a Shapiro, CL4 aut |
700 | 1 | a Andersen, KW4 aut |
700 | 1 | a Axelsson, CK4 aut |
700 | 1 | a Blichert-Toft, M4 aut |
700 | 1 | a Moller, S4 aut |
700 | 1 | a Mouridsen, HT4 aut |
700 | 1 | a Overgaard, J4 aut |
700 | 1 | a Overgaard, M4 aut |
700 | 1 | a Rose, C4 aut |
700 | 1 | a Cartensen, B4 aut |
700 | 1 | a Palshof, T4 aut |
700 | 1 | a Trampisch, HJ4 aut |
700 | 1 | a Dalesio, O4 aut |
700 | 1 | a de Vries, EGE4 aut |
700 | 1 | a Rodenhuis, S4 aut |
700 | 1 | a van Tinteren, H4 aut |
700 | 1 | a Comis, RL4 aut |
700 | 1 | a Davidson, NE4 aut |
700 | 1 | a Gray, R4 aut |
700 | 1 | a Robert, N4 aut |
700 | 1 | a Sledge, G4 aut |
700 | 1 | a Tormey, DC4 aut |
700 | 1 | a Wood, W4 aut |
700 | 1 | a Cameron, D4 aut |
700 | 1 | a Chetty, U4 aut |
700 | 1 | a Forrest, P4 aut |
700 | 1 | a Jack, W4 aut |
700 | 1 | a Rossbach, J4 aut |
700 | 1 | a Klijn, JGM4 aut |
700 | 1 | a Treurniet-Donker, AD4 aut |
700 | 1 | a van Putten, WLJ4 aut |
700 | 1 | a Costa, A4 aut |
700 | 1 | a Veronesi, U4 aut |
700 | 1 | a Bartelink, H4 aut |
700 | 1 | a Duchateau, L4 aut |
700 | 1 | a Legrand, C4 aut |
700 | 1 | a Sylvester, R4 aut |
700 | 1 | a van der Hage, JA4 aut |
700 | 1 | a van de Velde, CJH4 aut |
700 | 1 | a Cunningham, MP4 aut |
700 | 1 | a Catalano, R4 aut |
700 | 1 | a Creech, RH4 aut |
700 | 1 | a Bonneterre, J4 aut |
700 | 1 | a Fargeot, P4 aut |
700 | 1 | a Fumoleau, P4 aut |
700 | 1 | a Kerbrat, P4 aut |
700 | 1 | a Namer, M4 aut |
700 | 1 | a Jonat, W4 aut |
700 | 1 | a Kaufmann, M4 aut |
700 | 1 | a Schumacher, M4 aut |
700 | 1 | a von Minckwitz, G4 aut |
700 | 1 | a Bastert, G4 aut |
700 | 1 | a Rauschecker, H4 aut |
700 | 1 | a Sauer, R4 aut |
700 | 1 | a Sauerbrei, W4 aut |
700 | 1 | a Schauer, A4 aut |
700 | 1 | a Schumacher, M4 aut |
700 | 1 | a de Schryver, A4 aut |
700 | 1 | a Vakaet, L4 aut |
700 | 1 | a Belfiglio, M4 aut |
700 | 1 | a Nicolucci, A4 aut |
700 | 1 | a Pellegrini, F4 aut |
700 | 1 | a Sacco, M4 aut |
700 | 1 | a Valentini, M4 aut |
700 | 1 | a McArdle, CS4 aut |
700 | 1 | a Smith, DC4 aut |
700 | 1 | a Galligioni, E4 aut |
700 | 1 | a Boccardo, F4 aut |
700 | 1 | a Rubagotti, A4 aut |
700 | 1 | a Dent, DM4 aut |
700 | 1 | a Gudgeon, CA4 aut |
700 | 1 | a Hacking, A4 aut |
700 | 1 | a Erazo, A4 aut |
700 | 1 | a Medina, JY4 aut |
700 | 1 | a Izuo, M4 aut |
700 | 1 | a Morishita, Y4 aut |
700 | 1 | a Takei, H4 aut |
700 | 1 | a Fentiman, IS4 aut |
700 | 1 | a Hayward, JL4 aut |
700 | 1 | a Rubens, RD4 aut |
700 | 1 | a Skilton, D4 aut |
700 | 1 | a Graeff, H4 aut |
700 | 1 | a Janicke, F4 aut |
700 | 1 | a Meisner, C4 aut |
700 | 1 | a Scheurlen, H4 aut |
700 | 1 | a Kaufmann, M4 aut |
700 | 1 | a von Fournier, D4 aut |
700 | 1 | a Dafni, U4 aut |
700 | 1 | a Fountzilas, G4 aut |
700 | 1 | a Klefstrom, P4 aut |
700 | 1 | a Blomqvist, C4 aut |
700 | 1 | a Saarto, T4 aut |
700 | 1 | a Margreiter, R4 aut |
700 | 1 | a Asselain, B4 aut |
700 | 1 | a Salmon, RJ4 aut |
700 | 1 | a Vilcoq, JR4 aut |
700 | 1 | a Arriagada, R4 aut |
700 | 1 | a Hill, C4 aut |
700 | 1 | a Laplanche, A4 aut |
700 | 1 | a Le, MG4 aut |
700 | 1 | a Spielmann, M4 aut |
700 | 1 | a Bruzzi, P4 aut |
700 | 1 | a Montanaro, E4 aut |
700 | 1 | a Rosso, R4 aut |
700 | 1 | a Sertoli, MR4 aut |
700 | 1 | a Venturini, M4 aut |
700 | 1 | a Amadori, D4 aut |
700 | 1 | a Benraadt, J4 aut |
700 | 1 | a Kooi, M4 aut |
700 | 1 | a van de Velde, AO4 aut |
700 | 1 | a van Dongen, JA4 aut |
700 | 1 | a Vermorken, JB4 aut |
700 | 1 | a Castiglione, M4 aut |
700 | 1 | a Cavalli, F4 aut |
700 | 1 | a Coates, A4 aut |
700 | 1 | a Collins, J4 aut |
700 | 1 | a Forbes, J4 aut |
700 | 1 | a Gelber, RD4 aut |
700 | 1 | a Goldhirsch, A4 aut |
700 | 1 | a Lindtner, J4 aut |
700 | 1 | a Price, KN4 aut |
700 | 1 | a Rudenstam, CM4 aut |
700 | 1 | a Senn, HJ4 aut |
700 | 1 | a Bliss, JM4 aut |
700 | 1 | a Chilvers, CED4 aut |
700 | 1 | a Coombes, RC4 aut |
700 | 1 | a Hall, E4 aut |
700 | 1 | a Marty, M4 aut |
700 | 1 | a Borovik, R4 aut |
700 | 1 | a Brufman, G4 aut |
700 | 1 | a Hayat, H4 aut |
700 | 1 | a Robinson, E4 aut |
700 | 1 | a Wigler, N4 aut |
700 | 1 | a Bonadonna, G4 aut |
700 | 1 | a Camerini, T4 aut |
700 | 1 | a De Palo, G4 aut |
700 | 1 | a Del Vecchio, M4 aut |
700 | 1 | a Formelli, F4 aut |
700 | 1 | a Valagussa, P4 aut |
700 | 1 | a Martoni, A4 aut |
700 | 1 | a Pannuti, F4 aut |
700 | 1 | a Cocconi, G4 aut |
700 | 1 | a Colozza, A4 aut |
700 | 1 | a Camisa, R4 aut |
700 | 1 | a Aogi, K4 aut |
700 | 1 | a Takashima, S4 aut |
700 | 1 | a Abe, O4 aut |
700 | 1 | a Ikeda, T4 aut |
700 | 1 | a Inokuchi, K4 aut |
700 | 1 | a Kikuchi, K4 aut |
700 | 1 | a Sawa, K4 aut |
700 | 1 | a Sonoo, H4 aut |
700 | 1 | a Korzeniowski, S4 aut |
700 | 1 | a Skolyszewski, J4 aut |
700 | 1 | a Ogawa, M4 aut |
700 | 1 | a Yamashita, J4 aut |
700 | 1 | a Bonte, J4 aut |
700 | 1 | a Christiaens, R4 aut |
700 | 1 | a Paridaens, R4 aut |
700 | 1 | a Van den Boegart, W4 aut |
700 | 1 | a Martin, P4 aut |
700 | 1 | a Romain, S4 aut |
700 | 1 | a Hakes, T4 aut |
700 | 1 | a Hudis, CA4 aut |
700 | 1 | a Norton, L4 aut |
700 | 1 | a Wittes, R4 aut |
700 | 1 | a Giokas, G4 aut |
700 | 1 | a Kondylis, D4 aut |
700 | 1 | a Lissaios, B4 aut |
700 | 1 | a de la Huerta, R4 aut |
700 | 1 | a Sainz, MG4 aut |
700 | 1 | a Altemus, R4 aut |
700 | 1 | a Cowan, K4 aut |
700 | 1 | a Danforth, D4 aut |
700 | 1 | a Lichter, A4 aut |
700 | 1 | a Lippman, M4 aut |
700 | 1 | a O'Shaughnessy, J4 aut |
700 | 1 | a Pierce, LJ4 aut |
700 | 1 | a Steinberg, S4 aut |
700 | 1 | a Venzon, D4 aut |
700 | 1 | a Zujewski, J4 aut |
700 | 1 | a Paradiso, A4 aut |
700 | 1 | a De Lena, M4 aut |
700 | 1 | a Schittulli, F4 aut |
700 | 1 | a Myles, JD4 aut |
700 | 1 | a Pater, JL4 aut |
700 | 1 | a Pritchard, KI4 aut |
700 | 1 | a Nomura, Y4 aut |
700 | 1 | a Anderson, S4 aut |
700 | 1 | a Bass, G4 aut |
700 | 1 | a Brown, A4 aut |
700 | 1 | a Bryant, J4 aut |
700 | 1 | a Costantino, J4 aut |
700 | 1 | a Dignam, J4 aut |
700 | 1 | a Fisher, B4 aut |
700 | 1 | a Redmond, C4 aut |
700 | 1 | a Wieand, S4 aut |
700 | 1 | a Wolmark, N4 aut |
700 | 1 | a Baum, M4 aut |
700 | 1 | a Jackson, IM4 aut |
700 | 1 | a Palmer, MK4 aut |
700 | 1 | a Ingle, JN4 aut |
700 | 1 | a Suman, VJ4 aut |
700 | 1 | a Bengtsson, NO4 aut |
700 | 1 | a Jonsson, H4 aut |
700 | 1 | a Larsson, LG4 aut |
700 | 1 | a Lythgoe, JP4 aut |
700 | 1 | a Swindell, R4 aut |
700 | 1 | a Kissin, M4 aut |
700 | 1 | a Erikstein, B4 aut |
700 | 1 | a Hannisdal, E4 aut |
700 | 1 | a Jacobsen, AB4 aut |
700 | 1 | a Varhaug, JE4 aut |
700 | 1 | a Erikstein, B4 aut |
700 | 1 | a Gundersen, S4 aut |
700 | 1 | a Hauer-Jensen, M4 aut |
700 | 1 | a Host, H4 aut |
700 | 1 | a Jacobsen, AB4 aut |
700 | 1 | a Nissen-Meyer, R4 aut |
700 | 1 | a Blamey, RW4 aut |
700 | 1 | a Mitchell, AK4 aut |
700 | 1 | a Morgan, DAL4 aut |
700 | 1 | a Robertson, JFR4 aut |
700 | 1 | a Di Palma, M4 aut |
700 | 1 | a Mathe, G4 aut |
700 | 1 | a Misset, JL4 aut |
700 | 1 | a Clark, RM4 aut |
700 | 1 | a Levine, M4 aut |
700 | 1 | a Morimoto, K4 aut |
700 | 1 | a Sawa, K4 aut |
700 | 1 | a Takatsuka, Y4 aut |
700 | 1 | a Crossley, E4 aut |
700 | 1 | a Harris, A4 aut |
700 | 1 | a Talbot, D4 aut |
700 | 1 | a Taylor, M4 aut |
700 | 1 | a Cocconi, G4 aut |
700 | 1 | a di Blasio, B4 aut |
700 | 1 | a Ivanov, V4 aut |
700 | 1 | a Semiglazov, V4 aut |
700 | 1 | a Brockschmidt, J4 aut |
700 | 1 | a Cooper, MR4 aut |
700 | 1 | a Ueo, H4 aut |
700 | 1 | a Falkson, CI4 aut |
700 | 1 | a A'Hern, R4 aut |
700 | 1 | a Ashley, S4 aut |
700 | 1 | a Powles, TJ4 aut |
700 | 1 | a Smith, IE4 aut |
700 | 1 | a Yarnold, JR4 aut |
700 | 1 | a Gazet, JC4 aut |
700 | 1 | a Cocoran, N4 aut |
700 | 1 | a Deshpande, N4 aut |
700 | 1 | a di Martino, L4 aut |
700 | 1 | a Douglas, P4 aut |
700 | 1 | a Hacking, A4 aut |
700 | 1 | a Host, H4 aut |
700 | 1 | a Lindtner, A4 aut |
700 | 1 | a Notter, G4 aut |
700 | 1 | a Bryant, AJS4 aut |
700 | 1 | a Ewing, GH4 aut |
700 | 1 | a Firth, LA4 aut |
700 | 1 | a Krushen-Kosloski, JL4 aut |
700 | 1 | a Nissen-Meyer, R4 aut |
700 | 1 | a Foster, L4 aut |
700 | 1 | a George, WD4 aut |
700 | 1 | a Stewart, HJ4 aut |
700 | 1 | a Stroner, P4 aut |
700 | 1 | a Malmström, Peru Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-pma |
700 | 1 | a Möller, Torgilu Lund University,Lunds universitet,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)canc-tmo |
700 | 1 | a Ryden, S4 aut |
700 | 1 | a Tengrup, Ingridu Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine4 aut0 (Swepub:lu)med-itg |
700 | 1 | a Tennvall-Nittby, L4 aut |
700 | 1 | a Carstenssen, J4 aut |
700 | 1 | a Dufmats, M4 aut |
700 | 1 | a Hatschek, T4 aut |
700 | 1 | a Nordenskjold, B4 aut |
700 | 1 | a Soderberg, M4 aut |
700 | 1 | a Carpenter, JT4 aut |
700 | 1 | a Albain, K4 aut |
700 | 1 | a Crowley, J4 aut |
700 | 1 | a Green, S4 aut |
700 | 1 | a Martino, S4 aut |
700 | 1 | a Osborne, CK4 aut |
700 | 1 | a Ravdin, PM4 aut |
700 | 1 | a Glas, U4 aut |
700 | 1 | a Johansson, U4 aut |
700 | 1 | a Rutqvist, LE4 aut |
700 | 1 | a Singnomklao, T4 aut |
700 | 1 | a Wallgren, A4 aut |
700 | 1 | a Castiglione, M4 aut |
700 | 1 | a Goldhirsch, A4 aut |
700 | 1 | a Maibach, R4 aut |
700 | 1 | a Senn, HJ4 aut |
700 | 1 | a Thurlimann, B4 aut |
700 | 1 | a Brenner, H4 aut |
700 | 1 | a Hercbergs, A4 aut |
700 | 1 | a Yoshimoto, M4 aut |
700 | 1 | a DeBoer, G4 aut |
700 | 1 | a Paterson, AHG4 aut |
700 | 1 | a Pritchard, KI4 aut |
700 | 1 | a Meakin, JW4 aut |
700 | 1 | a Panzarella, T4 aut |
700 | 1 | a Pritchard, KI4 aut |
700 | 1 | a Shan, Y4 aut |
700 | 1 | a Shao, YF4 aut |
700 | 1 | a Wang, X4 aut |
700 | 1 | a Zhao, DB4 aut |
700 | 1 | a Boreham, J4 aut |
700 | 1 | a Chen, ZM4 aut |
700 | 1 | a Pan, HC4 aut |
700 | 1 | a Peto, R4 aut |
700 | 1 | a Bahi, J4 aut |
700 | 1 | a Reid, M4 aut |
700 | 1 | a Spittle, M4 aut |
700 | 1 | a Deutsch, GP4 aut |
700 | 1 | a Senanayake, F4 aut |
700 | 1 | a Kwong, DLW4 aut |
700 | 1 | a Bianco, AR4 aut |
700 | 1 | a Carlomagno, C4 aut |
700 | 1 | a De Laurentiis, M4 aut |
700 | 1 | a De Placido, S4 aut |
700 | 1 | a Buzdar, AU4 aut |
700 | 1 | a Smith, T4 aut |
700 | 1 | a Bergh, J4 aut |
700 | 1 | a Holmberg, L4 aut |
700 | 1 | a Liljegren, G4 aut |
700 | 1 | a Nilsson, J4 aut |
700 | 1 | a Seifert, M4 aut |
700 | 1 | a Sevelda, P4 aut |
700 | 1 | a Zielinsky, CC4 aut |
700 | 1 | a Buchanan, RB4 aut |
700 | 1 | a Cross, M4 aut |
700 | 1 | a Royle, GT4 aut |
700 | 1 | a Dunn, JA4 aut |
700 | 1 | a Hills, RK4 aut |
700 | 1 | a Lee, M4 aut |
700 | 1 | a Morrison, JM4 aut |
700 | 1 | a Spooner, D4 aut |
700 | 1 | a Litton, A4 aut |
700 | 1 | a Chlebowski, RT4 aut |
700 | 1 | a Caffier, H4 aut |
710 | 2 | a Bröstcancer-genetikb Sektion I4 org |
773 | 0 | t The Lancetg 365:9472, s. 1687-1717q 365:9472<1687-1717x 1474-547X |
856 | 4 | u http://dx.doi.org/10.1016/S0140-6736(05)66544-0y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/243217 |
856 | 4 8 | u https://doi.org/10.1016/S0140-6736(05)66544-0 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.